GPT and soft tissue sarcoma: DLTs: fatigue (3), hyponatremia (1), elevated ALT (1)MTD (step A): vorinostat 400 mg qd on Days 1–14 + bortezomib 1.3 mg/m2 on Days 1, 4, 8, and 11 of a 21-day cycleClinical activity observed: 1 PR >9 months in a patient with refractory soft tissue sarcoma